Connection

Co-Authors

This is a "connection" page, showing publications co-authored by BORJE S ANDERSSON and APOSTOLIA MARIA TSIMBERIDOU.
  1. Autologous engineered T cell receptor therapy in advanced cancer. Hum Vaccin Immunother. 2023 12 15; 19(3):2290356.
    View in: PubMed
    Score: 0.931
  2. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol. 2021 06 30; 14(1):102.
    View in: PubMed
    Score: 0.785
  3. Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. Int J Mol Sci. 2024 Aug 26; 25(17).
    View in: PubMed
    Score: 0.244
  4. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy. Oncotarget. 2024 Jun 03; 15:361-373.
    View in: PubMed
    Score: 0.241
  5. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J Hematol Oncol. 2023 10 25; 16(1):108.
    View in: PubMed
    Score: 0.231
  6. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J Immunother Cancer. 2024 Jul 22; 12(7).
    View in: PubMed
    Score: 0.061
  7. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunol Res. 2023 07 05; 11(7):925-945.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.